Korean Circ J.  1991 Aug;21(4):781-785. 10.4070/kcj.1991.21.4.781.

Effects of Lovastatin(Mevacor(R)) on Lowering Plasma Lipids in Patients with Hyperlipidemia

Abstract

Lovastatin, a competitive inhibitor of the rate limiting enzyme in cholesterol biosynthesis was administered to 34 patients with primary hypertlipidemia, 20 mg once daily with the evening meal. Patients experienced mean total and LDL cholesterol reductions of 30.9% and 34.0% respectively. HDL cholesterol level was significantly increased by 15.4% and plasma triglyceride level was decreased by 11.2%. maximal hypocholesterolemic effects were evident at 8 weeks, after which the effects were stable. Adverse effects were noted in 2 patients who had mild gastrointestinal symptoms, that subsided after discontinuing the drug. We concluded that lovastatin is a well tolerated and effective agent for the treatment of primary hyperlipidemia.

Keyword

Hypertlipidemia; Lovastatin

MeSH Terms

Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Humans
Hyperlipidemias*
Lovastatin
Meals
Plasma*
Triglycerides
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Lovastatin

Cited by  2 articles

Cholesterol Lowering Effects of Low-dose Statins in Korean Patients
Jee Eun Kwon, Young Kim, Seonghyup Hyun, Hoyoun Won, Seung Yong Shin, Kwang Je Lee, Sang-Wook Kim, Tae Ho Kim, Chee Jeong Kim
J Lipid Atheroscler. 2014;3(1):21-28.    doi: 10.12997/jla.2014.3.1.21.

2018 Guidelines for the Management of Dyslipidemia in Korea
Eun-Jung Rhee, Hyeon Chang Kim, Jae Hyeon Kim, Eun Young Lee, Byung Jin Kim, Eun Mi Kim, YoonJu Song, Jeong Hyun Lim, Hae Jin Kim, Seonghoon Choi, Min Kyong Moon, Jin Oh Na, Kwang-Yeol Park, Mi Sun Oh, Sang Youb Han, Junghyun Noh, Kyung Hee Yi, Sang-Hak Lee, Soon-Cheol Hong, In-Kyung Jeong,
J Lipid Atheroscler. 2019;8(2):78-131.    doi: 10.12997/jla.2019.8.2.78.

Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr